-

QIAGEN N.V. to Report Fourth Quarter and Full-Year 2020 Results

VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the fourth quarter and full-year 2020 on Tuesday, February 9,at approximately 22:05 Central European Time (CET) / 16:05 Eastern Standard Time (EST).

A conference call is planned for Wednesday, February 10, at 15:00 CET / 9:00 EST, hosted by Thierry Bernard, Chief Executive Officer, and Roland Sackers, Chief Financial Officer.

Conference call and webcast details

Interested parties may listen to the call by dialing:

+1 646 828 8193 (U.S.), +44 (0)330 336 9411 (UK), +49 (0)69 2222 2018 (Germany).

To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.

Conference ID: 2900586

The webcast will be accessible at:
https://globalmeet.webcasts.com/viewer/event.jsp?ei=1422345&tp_key=e2c7f9a1ee

A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/viewer/event.jsp?ei=1422345&tp_key=e2c7f9a1ee

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D, and industrial applications, primarily forensics). As of September 30, 2020, QIAGEN employed more than 5,300 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Contacts

John Gilardi
Vice President Head of Corporate Communications and Investor Relations
+49 2103 29 11711
+1 240 686 2222
Email: ir@qiagen.com

Phoebe Loh
Associate Director Investor Relations
+49 2103 29 11457
Email: ir@qiagen.com

Industry:

QIAGEN N.V.

FWB:QIA
Details
Headquarters: Venlo, Netherlands
CEO: Thierry Bernard
Employees: 5800
Organization: PUB
Revenues: US$ 1.97 billion (2023)
Net Income: US$ 341.3 million (2023)
Release Summary
QIAGEN N.V. to Report Fourth Quarter and Full-Year 2020 Results
Release Versions
English

Contacts

John Gilardi
Vice President Head of Corporate Communications and Investor Relations
+49 2103 29 11711
+1 240 686 2222
Email: ir@qiagen.com

Phoebe Loh
Associate Director Investor Relations
+49 2103 29 11457
Email: ir@qiagen.com

More News From QIAGEN N.V.

QIAGEN reports preliminary Q3 2026 results

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary third-quarter 2026 financial results. Net sales were $548 million at both reported and constant exchange rates (CER). Adjusted diluted earnings per share (EPS) were $0.65, also $0.65 CER. QIAGEN plans to report full Q3 2026 results on Wednesday, November 4, 2026, at approximately 22:05 Frankfurt time / 16:05 New York time. Given the announced transaction wit...

QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer

VENLO, Netherlands & AMSTERDAM--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) and the EQT XI fund (“EQT Private Equity”) today announced an agreement under which Crown NL Bidco B.V. (the “Bidder”) announced its decision to make an all-cash voluntary public takeover offer for the acquisition of all outstanding QIAGEN shares at €46.50 per share (the “Takeover Offer”). The Bidder is a holding company indirectly controlled by EQT XI fund with f...

QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) will bring together tuberculosis experts from around the world for the Global TB Clinical and Educational Summit from October 13-16 as a persistent disease burden and growing pressures on global health funding put renewed focus on tuberculosis prevention, screening and care. An estimated 10.7 million people worldwide developed tuberculosis in 2024 and nearly 1.2 million died from the d...
Back to Newsroom